These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20164689)

  • 1. BRCA gene structure and function in tumor suppression: a repair-centric perspective.
    Murphy CG; Moynahan ME
    Cancer J; 2010; 16(1):39-47. PubMed ID: 20164689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
    Bodily WR; Shirts BH; Walsh T; Gulsuner S; King MC; Parker A; Roosan M; Piccolo SR
    PLoS One; 2020; 15(9):e0239197. PubMed ID: 32997669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic exploitation of tumor cell defects in homologous recombination.
    Powell SN; Kachnic LA
    Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
    Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PALB2 is an integral component of the BRCA complex required for homologous recombination repair.
    Sy SM; Huen MS; Chen J
    Proc Natl Acad Sci U S A; 2009 Apr; 106(17):7155-60. PubMed ID: 19369211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the DNA repair defect of BRCA tumours.
    Turner N; Tutt A; Ashworth A
    Curr Opin Pharmacol; 2005 Aug; 5(4):388-93. PubMed ID: 15955736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homologous repair deficiency score for identifying breast cancers with defective DNA damage response.
    Min A; Kim K; Jeong K; Choi S; Kim S; Suh KJ; Lee KH; Kim S; Im SA
    Sci Rep; 2020 Jul; 10(1):12506. PubMed ID: 32719318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The RAD52 S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations.
    Adamson AW; Ding YC; Mendez-Dorantes C; Bailis AM; Stark JM; Neuhausen SL
    Mol Oncol; 2020 Jun; 14(6):1124-1133. PubMed ID: 32175645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homologous repair of DNA damage and tumorigenesis: the BRCA connection.
    Jasin M
    Oncogene; 2002 Dec; 21(58):8981-93. PubMed ID: 12483514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [BRCA1 and BRCA2 - pathologists starting kit].
    Škapa P
    Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition.
    Tutt A; Ashworth A
    Trends Mol Med; 2002 Dec; 8(12):571-6. PubMed ID: 12470990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
    Maxwell KN; Wubbenhorst B; Wenz BM; De Sloover D; Pluta J; Emery L; Barrett A; Kraya AA; Anastopoulos IN; Yu S; Jiang Y; Chen H; Zhang NR; Hackman N; D'Andrea K; Daber R; Morrissette JJD; Mitra N; Feldman M; Domchek SM; Nathanson KL
    Nat Commun; 2017 Aug; 8(1):319. PubMed ID: 28831036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.
    Chalasani P; Livingston R
    Oncologist; 2013; 18(8):909-16. PubMed ID: 23881989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.
    Plevova P; Cerna D; Balcar A; Foretova L; Zapletalova J; Silhanova E; Curik R; Dvorackova J
    Neoplasma; 2010; 57(4):325-32. PubMed ID: 20429623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABRAXAS1 orchestrates BRCA1 activities to counter genome destabilizing repair pathways-lessons from breast cancer patients.
    Sachsenweger J; Jansche R; Merk T; Heitmeir B; Deniz M; Faust U; Roggia C; Tzschach A; Schroeder C; Riess A; Pospiech H; Peltoketo H; Pylkäs K; Winqvist R; Wiesmüller L
    Cell Death Dis; 2023 May; 14(5):328. PubMed ID: 37198153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presymptomatic breast cancer in Egypt: role of BRCA1 and BRCA2 tumor suppressor genes mutations detection.
    Ibrahim SS; Hafez EE; Hashishe MM
    J Exp Clin Cancer Res; 2010 Jun; 29(1):82. PubMed ID: 20579331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The biological effects and clinical implications of BRCA mutations: where do we go from here?
    Stoppa-Lyonnet D
    Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S3-9. PubMed ID: 27514841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1/2 testing: therapeutic implications for breast cancer management.
    Tung NM; Garber JE
    Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1 and BRCA2 protect against oxidative DNA damage converted into double-strand breaks during DNA replication.
    Fridlich R; Annamalai D; Roy R; Bernheim G; Powell SN
    DNA Repair (Amst); 2015 Jun; 30():11-20. PubMed ID: 25836596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.